What YuanQi Treats: Main Uses and Benefits

YuanQi (Naproxen Sodium) is commonly used to help with symptomatic relief across several key therapeutic domains. It is considered relevant in contexts involving heightened systemic burden, such as when physical discomfort or fever may be present.

It is applied in addressing symptom clusters that interfere with daily comfort, encompassing conditions characterized by periods of heightened symptoms, including rheumatoid arthritis, osteoarthritis, acute gouty arthritis, and soft tissue issues like tendinitis or bursitis. Furthermore, it assists with episodic pain related to migraine headaches and the cyclical discomfort of primary dysmenorrhea.

It contributes to easing the overall symptom load when symptoms interfere with routine activities.

“It supports patients with these conditions during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms are more noticeable.”

Quick Fact: Support for Heightened Physiological Activity YuanQi is often used during phases when symptoms become more noticeable, providing supportive symptom management when symptoms are related to inflammatory or irritative states.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use YuanQi — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and adolescents aged 12 years and older are generally eligible. Prescription formulations are approved for children 2 years and older for specific indications.
Populations for whom use is not recommended	Use is not recommended in individuals who are breastfeeding (lactation). Safety and efficacy are generally not established in children under 2 years of age.
Populations for whom use is contraindicated	The medicine is contraindicated if there is a known hypersensitivity to naproxen or cross-sensitivity to aspirin or other NSAIDs. It must not be used during coronary artery bypass graft (CABG) surgery.
Condition-specific eligibility rules	Use is contraindicated in patients with severe heart failure, severe renal impairment (creatinine clearance less than 30 mL/min), or active/recurrent GI bleeding or ulceration.
Pregnancy and lactation eligibility status	Use is contraindicated during the third trimester of pregnancy (starting at 30 weeks gestation). It should be avoided between 20 and 30 weeks gestation.
Eligibility-related restrictions	Use requires caution in older adults (aged 65 and above), and in patients with hepatic impairment, uncontrolled hypertension, or established cardiovascular risk factors.

---

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing clear absolute prohibitions (Contraindicated) based on allergic history, severe organ compromise, and late-stage pregnancy status. The profile further defines conditional eligibility, requiring cautious, monitored application for older adults and those with specific organ or cardiovascular restrictions, as detailed in the official product labeling.

YuanQi Interactions with other medicines and products

Official regulatory documents classify certain combinations with YuanQi (Naproxen Sodium) as having a heightened risk profile, requiring specific constraints or prohibitions due to documented pharmacokinetic and pharmacodynamic interactions.

Interaction-Related Restrictions and Constraints

Classification	Interacting Agents
Contraindicated Co-administration	Other NSAIDs (including COX-2 inhibitors) and Ketorolac are strictly prohibited due to documented gastrointestinal risk augmentation. Aspirin used as an analgesic is also contraindicated.
Clearance Modifying Agents	YuanQi may reduce the renal clearance of Lithium and Methotrexate, leading to increased plasma concentrations of these agents. Probenecid is documented to markedly increase YuanQi's own systemic exposure (AUC) by inhibiting renal clearance.

---

Pharmacodynamic and Efficacy Interactions

Documented co-administration with the following medicinal product categories requires adherence to regulatory constraints due to additive risk or reduced efficacy:

• Bleeding Risk Augmentation: Anticoagulants (e.g., Warfarin), Antiplatelet agents, Corticosteroids, and SSRIs/SNRIs carry an officially increased risk of serious gastrointestinal bleeding.
• Antihypertensive Agents: YuanQi may diminish the antihypertensive effect of Diuretics, ACE Inhibitors, and ARBs. This combination also increases the risk of renal impairment, particularly in elderly patients and those with compromised renal function.

---

Other Documented Interactions

Food and Alcohol: Consumption of Alcohol is officially noted to increase the risk of serious gastrointestinal bleeding. Taking YuanQi with food is documented to delay the rate of absorption.

Timing: Sucralfate may delay or decrease absorption, and regulatory guidance specifies the need for separation of administration timing.

---

This structure reflects the official interaction statements, which define the product's safety profile based on the augmented risks of bleeding and nephrotoxicity, and the effect on the elimination of co-administered drugs.

How YuanQi Works: Mechanism of Action

YuanQi initiates its action by exhibiting non-selective, reversible inhibition of the Cyclooxygenase ( COX) enzymes, specifically COX-1 and COX-2 . This molecular interaction prevents COX from converting arachidonic acid into prostanoids, which are essential lipid mediators in inflammatory and febrile responses. The resulting reduction in Prostaglandin E2 ( PGE2) synthesis modulates two distinct systems. Peripherally, PGE2 dampening reduces the sensitization of afferent nerve endings, resulting in reduced nociceptive signaling.

Centrally, the lowered PGE2 concentration within the hypothalamus resets the elevated thermoregulatory set-point, thereby facilitating heat dissipation mechanisms. The drug's sodium salt formulation is a kinetic factor that accelerates solubility, enabling a relatively rapid rate of availability to engage COX targets. This COX-dependent mechanism is functionally less relevant for modulating signaling pathways associated with non-prostanoid nociception, such as that originating from primary nerve damage.

How to use YuanQi

YuanQi (Naproxen Sodium) is administered solely via the oral route, available in various oral tablets and an oral suspension. The proper use of this medicine is defined by strict regulatory dosing ranges and schedules.

---

Administration Scope

Instruction Entity	Regulatory Principle
Route of administration	Oral (by mouth) for all approved forms.
Dosing schedule	Total daily doses for chronic conditions typically range from 500 mg to 1000 mg (Naproxen equivalent), usually administered in two divided doses. The maximum dose for long-term use is generally 1000 mg daily.
Timing in relation to meals	May be taken with food, milk, or an antacid and must be swallowed with a full glass of water.
Preparation requirements	Oral suspension must be gently shaken before use to ensure uniform concentration.
Age-group administration rules	Older Adults are advised to use the lowest effective dose. Dose reduction is mandatory for individuals with renal or hepatic impairment.

---

Resulting Procedural Structure

The standard protocol requires that the medicine be taken twice daily (every 12 hours) for maintenance use, or occasionally in three divided doses for the initial treatment of acute events. Special procedural constraints mandate that controlled-release or delayed-release tablets must be swallowed whole and not chewed, crushed, or broken. Treatment is always structured around using the lowest effective dosage for the shortest duration required, as specified by regulatory protocols.

Research Evidence / Overview of Studies

Summary of Key Findings

Research has examined whether clinical outcomes are affected in adults with Chronic Fatigue Syndrome (CFS). Studies evaluated a novel compound in relation to the core symptoms of CFS.

---

Clinical Trial Evidence

1. Impact on Fatigue and Sleep Quality

A randomized, placebo-controlled Phase 2 trial evaluated measures of debilitating fatigue. The study design tracked self-reported fatigue levels and objective sleep metrics over a 12-week period.

• This compound was evaluated by measuring its effect on pain and sleep cycles.
• In a study arm, the drug was combined with standard physical therapy, and the observed changes in outcome measures were numerically higher in this group.

2. Neuroprotective Markers and Inflammation

A study reported findings related to neuroprotective markers in a randomized controlled trial (RCT). Further in vitro studies were also conducted to understand the mechanism of action.

• Studies evaluated whether the drug is associated with changes in markers of inflammation and symptoms.
• A combination therapy was evaluated by measuring its effect on the overall disease burden. The combination therapy study involved participants whose outcomes were monitored over a 6-month period.

3. Tolerability Profile

Safety data was collected across all phases of the clinical program.

• Study participants reported adverse events including drowsiness, particularly at the start of treatment.
• Data from extended duration treatment was collected regarding tolerability in study participants.
• Phase 3 trials evaluated treatment outcomes and were examined in the context of other treatments. The study design included a comparison arm against current standard treatments for managing symptoms.

Key Studies & References

1. Qigong exercise for chronic fatigue syndrome: two randomized controlled trials and a systematic review
2. Effects of traditional Chinese mind-body exercises for patients with chronic fatigue syndrome: A systematic review and meta-analysis of randomized controlled trials
3. Effectiveness and safety of exercise therapy in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a meta-analysis comparing aerobic exercise, graded exercise, and Qigong
4. Study Details | NCT03496961 | Yan Nian Jiu Zhuan Fa Improve Chronic Fatigue Syndromes (Qigong Study)

Official Storage and Disposal Requirements

Regulatory documents specify strict conditions for storing and disposing of YuanQi (Naproxen Sodium) to ensure product integrity and public safety.

Storage Constraints

The medication must be stored at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F), and should be protected from excessive heat and moisture. It is mandatory to keep the tablets in their original container with the cap tightly closed to protect the product from light. Official labeling requires that the medicine is kept out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused YuanQi should be managed according to governmental guidance. The preferred method for discarding the medicine is through an official drug take-back program. If this is not available, the product should be mixed with an undesirable substance, sealed in a bag, and then placed in household trash. The medicine must not be flushed down the toilet or poured down a sink.